Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy

被引:32
|
作者
Sisti, Eleonora [1 ,2 ]
Coco, Barbara [3 ]
Menconi, Francesca [1 ,2 ]
Leo, Marenza [1 ,2 ]
Rocchi, Roberto [1 ,2 ]
Latrofa, Francesco [1 ,2 ]
Profilo, Maria Antonietta [1 ,2 ]
Mazzi, Barbara [1 ,2 ]
Vitti, Paolo [1 ,2 ]
Marcocci, Claudio [1 ,2 ]
Brunetto, Maurizia [3 ]
Marino, Michele [1 ,2 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, Endocrinol Units, I-56124 Pisa, Italy
[2] Univ Hosp Pisa, I-56124 Pisa, Italy
[3] Univ Hosp Pisa, Hepatol Unit, Pisa, Italy
关键词
AUTOIMMUNE HEPATITIS; METHYLPREDNISOLONE; OPHTHALMOPATHY; MANAGEMENT; PATIENT; DISEASE;
D O I
10.1089/thy.2015.0061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: High-dose intravenous glucocorticoid (ivGC) pulse therapy, which is commonly used for Graves' orbitopathy (GO), has been associated with acute liver damage (ALD), resulting in a fatal outcome in a few cases. No certain risk factors for ALD have been established. Consequently, a large retrospective cohort study was performed. Methods: The relationship between ALD and several potential risk factors was assessed in 1076 consecutive patients with GO given ivGC. ALD was defined as an increase of alanine aminotransferase 300IU/L. Results: Fourteen cases of ALD were recorded, resulting in a morbidity of 1.3%. Thirteen patients recovered and one died, resulting in a mortality of 0.09%. There was a significant, positive correlation of ALD with age and methylprednisolone acetate (MPA) cumulative dose, and ALD was more common (relative risk [RR]=2.8; p=0.05) in patients aged 53 years (9/420; 2.14%) than in those aged <53 years (5/656; 0.76%). In patients aged 53 years, there was a significant positive correlation of ALD with MPA cumulative dose, and with MPA dose per infusion. Thus, the frequency of ALD in this age group was greater (RR=3.48; p=0.04) in patients with a MPA dose per infusion 0.7g (5/111, 4.5% vs. 4/308, 1.29%). Regardless of age, no cases of ALD were observed for MPA doses per infusion <0.57g. Conclusions: Age and MPA dose are significant risk factors for ALD, with the following practical implications. First, the total MPA cumulative dose should not exceed 8.5g (the average dose in patients without ALD). Second, in patients aged 53 years, selection and observation should be quite strict. However, being aged 53 years should not be seen as an absolute contraindication to ivGC, especially in patients with severe GO, considering that the risk of ALD, although statistically significant, was relatively low. Third, the MPA dose should not exceed 0.57g per infusion, a measure to be applied regardless of age.
引用
收藏
页码:846 / 850
页数:5
相关论文
共 50 条
  • [1] Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy
    Sabini, E.
    Sisti, E.
    Coco, B.
    Leo, M.
    Ionni, I.
    Menconi, F.
    Profilo, M. A.
    Mazzi, B.
    Rocchi, R.
    Latrofa, F.
    Vitti, P.
    Brunetto, M.
    Marcocci, C.
    Marino, M.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2016, 39 (11) : 1323 - 1327
  • [2] Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves’ orbitopathy
    E. Sabini
    E. Sisti
    B. Coco
    M. Leo
    I. Ionni
    F. Menconi
    M. A. Profilo
    B. Mazzi
    R. Rocchi
    F. Latrofa
    P. Vitti
    M. Brunetto
    C. Marcocci
    M. Marinò
    Journal of Endocrinological Investigation, 2016, 39 : 1323 - 1327
  • [3] Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy
    Eguchi, Hiroyuki
    Tani, Junichi
    Hirao, Saori
    Tsuruta, Munehisa
    Tokubuchi, Ichiro
    Yamada, Kentaro
    Kasaoka, Masataka
    Teshima, Yasuo
    Kakuma, Tatsuyuki
    Hiromatsu, Yuji
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [4] Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy
    Marinó, M
    Morabito, E
    Brunetto, MR
    Bartalena, L
    Pinchera, A
    Marocci, C
    THYROID, 2004, 14 (05) : 403 - 406
  • [5] Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe?
    Miskiewicz, Piotr
    Kryczka, Adrianna
    Ambroziak, Urszula
    Rutkowska, Beata
    Glowczynska, Renata
    Opolski, Grzegorz
    Kahaly, George
    Bednarczuk, Tomasz
    ENDOKRYNOLOGIA POLSKA, 2014, 65 (05) : 402 - 413
  • [6] Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy
    Le Moli, Rosario
    Baldeschi, Lelio
    Saeed, Peerooz
    Regensburg, Noortje
    Mourits, Maarten P.
    Wiersinga, Wilmar M.
    THYROID, 2007, 17 (04) : 357 - 362
  • [7] Dose of intravenous steroids and therapy outcome in Graves’ orbitopathy
    S. Zang
    K. A. Ponto
    S. Pitz
    G. J. Kahaly
    Journal of Endocrinological Investigation, 2011, 34 : 876 - 880
  • [8] Dose of intravenous steroids and therapy outcome in Graves' orbitopathy
    Zang, S.
    Ponto, K. A.
    Pitz, S.
    Kahaly, G. J.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2011, 34 (11) : 876 - 880
  • [9] Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study
    Sisti, Eleonora
    Coco, Barbara
    Menconi, Francesca
    Leo, Marenza
    Rocchi, Roberto
    Latrofa, Francesco
    Profilo, Maria Antonietta
    Mazzi, Barbara
    Albano, Eleonora
    Vitti, Paolo
    Marcocci, Claudio
    Brunetto, Maurizia
    Marino, Michele
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (03) : 269 - 276
  • [10] Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy
    Miskiewicz, Piotr
    Jankowska, Anna
    Brodzinska, Kinga
    Milczarek-Banach, Justyna
    Ambroziak, Urszula
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2018, 2018